FIGHTING AGAINST
Nonalcoholic Steatohepatitis

Nonalcoholic Steatohepatitis (NASH), a type of fatty liver disease, affects between 3 to 12 percent of Americans.1 By 2020, it’s estimated NASH will overtake Hepatitis C as the leading cause of liver transplants in America. The disease is caused by the buildup of fat in the liver, resulting in inflammation and tissue damage.

The NASH Alliance is a coalition of clinical experts, patients and life sciences innovators focused on educating policymakers and the public on non-alcoholic steatohepatitis (NASH) and advocating responsible policies to improve treatment and prevention.

1. U.S. Department of Health and Human Services National Institute of Diabetes and Digestive and Kidney Diseases. Updated November 2016. https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/definition-facts

Questions? Want more information?

Please contact us at info@nashalliance.com or by filling out the form below: